UBS update for ( ASX:CSL) CSL Limited (ASX: CSL)The first blue...

UBS update for ( ASX:CSL)

CSL Limited (ASX: CSL)The first blue chip ASX 200 share to look at is biotherapeutics giant CSL. Its shares have come under pressure recently and are trading well below their 52-week high.This has been driven partly by its half year results last month. For the six months ended 31 December, CSL revealed a 16.9% increase in revenue to US$5,739 million and a massive 45% jump in net profit after tax to US$1,810 million. While this was far stronger than expected, to the disappointment of the market, management only held firm with its guidance for FY 2021. It expects net profit after tax of US$2,170 million to US$2,265 million in constant currency for the full year. This represents year on year growth of just 3% to %, which will mean a sharp decline in its performance in the second half.However, UBS remains positive on its long term growth and sees this share price weakness as a buying opportunity. It recently reaffirmed its buy rating but trimmed its price target slightly to $330.00